Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment

• Status: Completed
• Trial end date: 2021-02-25
• Target enrollment: 0
• Participant gender: All

Summary

The present study is designed for patients with mild COVID-19 phase, to demonstrate if there is a modification in the clinical evolution greater than or equal to 25% in their symptoms, implemented in two groups of patients under an early intervention treatment, a group ( A) will receive Azithromycin / Ivermectin / Ribaroxaban / Paracetamol and another group (B) will receive Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gilberto Cruz Arteaga
• Collaborator: Coordinación de Investigación en Salud, Mexico
• Treatments: Acetaminophen; Azithromycin; Ivermectin

Criteria

Inclusion Criteria:

• Patients Eligible for Family Medicine Unit No.20 and Family Medicine Unit No.13 belonging to the North DF of the IMSS.

• Male and female patients

• Patients over 18 years of age.

• Patients with compliance with the operational definition COVID-19 and confirmatory test of P.C.R. positive within the first days of the illness (that are evaluated in first level of medical attention).

• Patients with comorbidities such as Type 2 Diabetes Mellitus, Systemic Arterial Hypertension, Overweight or Obesity.

• That they agree to sign an informed consent

• Related to Video Call:

• That the Family Medicine Unit No.20 and the Family Medicine Unit No.13 belonging to the North DF of the IMSS have the Installation of Electronic Equipment for Internet use

Exclusion Criteria:

• Severe COVID-19 patients (Ameriten sent immediately to second level of care, hospital) Patients with any Personal Pathological History of Hematological Diseases. • Patients allergic to macrolides (Azithromycin) and Ivermectin.